Mentored Patient-Oriented Research Career Development Aw
指导以患者为中心的研究职业发展Aw
基本信息
- 批准号:6754466
- 负责人:
- 金额:$ 12.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:ACE inhibitorsangiographyantihypertensive agentscardiovascular disorder chemotherapycareerclinical researchclinical trialscombination chemotherapycooperative studydisease /disorder etiologydrug screening /evaluationhemodynamicshuman subjecthuman therapy evaluationpathologic processpharmacokineticsplacebosplasminogen activator inhibitorsprostacyclinsprostaglandinspulmonary circulationpulmonary hypertensionrenin angiotensin systemsclerodermathromboxanes
项目摘要
(Adapted from the applicant's abstract): PPH is a disease of high
morbidity and mortality occurring predominately in young adult women. The
etiology of this illness remains unknown, but increased production of
thromboxane A(2) [TxA(2)] and decreased synthesis of prostacyclin
[prostaglandin I] provide clues to the pathogenesis. Over the past decade,
intravenous epoprostenol, the synthetic analogue of prostacyclin, has emerged
as the most effective treatment of PPH. However, tolerance to the effects of
epoprostenol occurs in the majority of patients necessitating progressive
dose escalation to maintain efficacy. Furthermore, only 70% of patients
benefit from treatment. Preliminary data derived from clinical studies of
patients with PPH demonstrate that epoprostenol increases circulating levels
of angiotensin II (AII), a potent vasoconstrictor and smooth muscle mitogen,
which can stimulate production of both plasminogen activator inhibitor 1 (PAI-
1), a procoagulant protein, and vascular endothelial growth factor (VEGF),
permeability and angiogenic growth factor.
This proposal will explore two hypotheses: 1) activation of the renin-
angiotensin system (RAS) during chronic administration of epoprostenol is the
cause of increasing dose requirements; 2) direct and indirect effects of RAS
activation and persistent TxA(2) production limit the clinical efficacy of
epoprostenol. To evaluate these hypotheses, the applicant will: a) delineate
the relationship between epoprostenol-induced RAS activation and compare
biochemical changes with hemodynamic data obtained during right heart
catheterization; b) delineate clinical data obtained from measurement of
distance walked in six minutes, and structural changes obtained by wedge
angiography of pulmonary circulation; and c) determine, in a collaborative
study with other medical centers, whether concomitant treatment with and
angiotensin converting enzyme inhibitor will improve the clinical efficacy of
epoprostenol and prevent the need for chronic dose escalation. These studies
will advance our knowledge of the mechanism of action of epoprostenol and
pulmonary hypertension.
(改编自申请人的摘要):PPH是一种高度
发病率和死亡率主要发生在年轻成年妇女中。这个
这种疾病的病因尚不清楚,但产量增加
血栓素A(2)[TXA(2)]与前列环素合成减少
[前列腺素I]为发病机制提供线索。在过去的十年里,
静脉注射前列腺素,前列环素的合成类似物,已经出现
被认为是治疗PPH最有效的方法。然而,对
依前列烯醇存在于大多数需要进展性治疗的患者中
剂量递增以维持疗效。此外,只有70%的患者
从治疗中受益。来自临床研究的初步数据
产后增生症患者显示环前列烯醇可增加循环水平
血管紧张素II(AII),一种有效的血管收缩和平滑肌有丝分裂原,
它可以刺激纤溶酶原激活物抑制物1(PAI-1)的产生
1)、促凝血蛋白和血管内皮生长因子(VEGF),
通透性和血管生成生长因子。
这项提议将探索两个假设:1)肾素激活-
血管紧张素系统(RAS)在慢性给药中的作用
剂量需求增加的原因;2)RAS的直接和间接影响
活化和持续的TXA(2)产生限制了临床疗效
依波前列烯醇。为了评估这些假设,申请人将:a)描述
环前列烯醇诱导的RAS激活与比较
右心血流动力学数据的生化变化
导尿术;b)描述通过测量
距离步行6分钟,楔子获得结构变化
肺循环的血管造影术;以及c)在合作中确定
与其他医疗中心研究,是否同时治疗和
血管紧张素转换酶抑制剂将提高心力衰竭的临床疗效
依波前列烯醇和预防慢性剂量增加的需要。这些研究
将促进我们对环前列烯醇的作用机制的了解
肺动脉高压。
项目成果
期刊论文数量(293)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.
- DOI:10.1183/09031936.00010409
- 发表时间:2009-11
- 期刊:
- 影响因子:0
- 作者:Austin ED;Cogan JD;West JD;Hedges LK;Hamid R;Dawson EP;Wheeler LA;Parl FF;Loyd JE;Phillips JA 3rd
- 通讯作者:Phillips JA 3rd
Delirium: is sleep important?
- DOI:10.1016/j.bpa.2012.08.005
- 发表时间:2012-09
- 期刊:
- 影响因子:0
- 作者:Watson PL;Ceriana P;Fanfulla F
- 通讯作者:Fanfulla F
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
- DOI:10.1016/j.radonc.2005.04.005
- 发表时间:2005-07
- 期刊:
- 影响因子:0
- 作者:K. Tedesco;J. Berlin;M. Rothenberg;H. Choy;K. Wyman;Adrian Scott Pearson;R. Daniel Beauchamp;N. Merchant;A. Lockhart;Y. Shyr;Carol Caillouette;B. Chakravarthy
- 通讯作者:K. Tedesco;J. Berlin;M. Rothenberg;H. Choy;K. Wyman;Adrian Scott Pearson;R. Daniel Beauchamp;N. Merchant;A. Lockhart;Y. Shyr;Carol Caillouette;B. Chakravarthy
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.
- DOI:10.1016/j.vaccine.2009.03.015
- 发表时间:2009-11-05
- 期刊:
- 影响因子:5.5
- 作者:Keitel WA;Dekker CL;Mink C;Campbell JD;Edwards KM;Patel SM;Ho DY;Talbot HK;Guo K;Noah DL;Hill H
- 通讯作者:Hill H
alpha-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans.
α-酮异己酸在减少人类葡萄糖利用方面优于亮氨酸。
- DOI:10.1152/ajpendo.1986.251.6.e648
- 发表时间:1986
- 期刊:
- 影响因子:0
- 作者:Buckspan,R;Hoxworth,B;Cersosimo,E;Devlin,J;Horton,E;Abumrad,N
- 通讯作者:Abumrad,N
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ivan M Robbins其他文献
Ivan M Robbins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ivan M Robbins', 18)}}的其他基金
IXth International Pulmonary Hypertension Conference: Scientific Sessions
第九届国际肺动脉高压会议:科学会议
- 批准号:
8007167 - 财政年份:2010
- 资助金额:
$ 12.48万 - 项目类别:
A PILOT STUDY COMPARING ANTI-PLATELET THERAPIES AND PLACEBO IN PULMONARY ARTE
比较肺动脉疾病中抗血小板疗法和安慰剂的试点研究
- 批准号:
7207236 - 财政年份:2004
- 资助金额:
$ 12.48万 - 项目类别:
Evaluation of Circulating Lipid and Protein Mediators in Patients
患者循环脂质和蛋白质介质的评估
- 批准号:
7041377 - 财政年份:2003
- 资助金额:
$ 12.48万 - 项目类别:
A pilot study comparing anti-platelet therapies and placebo in pulmonary arte...
一项比较抗血小板疗法和安慰剂治疗肺动脉疾病的初步研究...
- 批准号:
7041425 - 财政年份:2003
- 资助金额:
$ 12.48万 - 项目类别:
Mentored Patient-Oriented Research Career Development Aw
指导以患者为中心的研究职业发展Aw
- 批准号:
6033387 - 财政年份:2000
- 资助金额:
$ 12.48万 - 项目类别:
Mentored Patient-Oriented Research Career Development Aw
指导以患者为中心的研究职业发展Aw
- 批准号:
6639888 - 财政年份:2000
- 资助金额:
$ 12.48万 - 项目类别:
Mentored Patient-Oriented Research Career Development Aw
指导以患者为中心的研究职业发展Aw
- 批准号:
6540670 - 财政年份:2000
- 资助金额:
$ 12.48万 - 项目类别:
Mentored Patient-Oriented Research Career Development Aw
指导以患者为中心的研究职业发展Aw
- 批准号:
6394798 - 财政年份:2000
- 资助金额:
$ 12.48万 - 项目类别:
相似海外基金
ImproviNg rEnal outcomes following coronary angiograPhy and/or percuTaneoUs coroNary intErventions: a pragmatic, adaptive, patient-oriented randomized controlled trial
改善冠状动脉造影和/或经皮冠状动脉介入治疗后的肾脏结局:一项务实、适应性、以患者为导向的随机对照试验
- 批准号:
478732 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Operating Grants
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
SBIR Phase II: Novel size-changing, gadolinium-free contrast agent for magnetic resonance angiography
SBIR II 期:用于磁共振血管造影的新型尺寸变化、无钆造影剂
- 批准号:
2322379 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Cooperative Agreement
Manipulation of Host Tissue to Induce a Hierarchical Microvasculature
操纵宿主组织以诱导分层微脉管系统
- 批准号:
10637683 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Non-invasive vagus nerve stimulation to mitigate subarachnoid hemorrhage induced inflammation
无创迷走神经刺激减轻蛛网膜下腔出血引起的炎症
- 批准号:
10665166 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Diversity Supplement: Manipulation of Host Tissue to Induce a Hierarchical Microvasculature
多样性补充:操纵宿主组织以诱导分层微血管系统
- 批准号:
10851311 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Molecular predictors of cardiovascular events and resilience in chronic coronary artery disease
心血管事件的分子预测因素和慢性冠状动脉疾病的恢复力
- 批准号:
10736587 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Quantitative Detection of Coronary Microvascular Dysfunction in Long COVID Patients using a Comprehensive, Rapid, Free-Breathing Cardiovascular MRI
使用全面、快速、自由呼吸的心血管 MRI 定量检测长期新冠肺炎患者的冠状动脉微血管功能障碍
- 批准号:
10671235 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Redefining cardiovascular risk assessment in dialysis patients (ROCK-D) study
重新定义透析患者心血管风险评估(ROCK-D)研究
- 批准号:
10564245 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别:
Neonatal Optical Coherence Tomography Angiography to Assess the Effects of Postnatal Exposures on Retinal Development and Predict Neurodevelopmental Outcomes
新生儿光学相干断层扫描血管造影评估产后暴露对视网膜发育的影响并预测神经发育结果
- 批准号:
10588086 - 财政年份:2023
- 资助金额:
$ 12.48万 - 项目类别: